Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Sands

Showing results (151-160 of 513) with videos related to

Pageof 52
Sort By:
Journal of Crohn'S & Colitis|May 28, 2013
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care centerAndrew Tinsley, Steven Naymagon, Laura M Enomoto, et al.
The Journal of Biological Chemistry|April 21, 1995
Molecular cloning of the rat intestinal trefoil factor gene. Characterization of an intestinal goblet cell-associated promoterB E Sands, H Ogata, K Lynch-Devaney, et al.
Scandinavian Journal of Gastroenterology|June 26, 2020
Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic studyRobert P Hirten, Simran Mashiana, Benjamin L Cohen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative ColitisParambir S Dulai, Brian G Feagan, Bruce E Sands, et al.
Clinical Pharmacology and Therapeutics|March 15, 2024
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug InteractionsJie Shao, Marion Vetter, An Vermeulen, et al.
Journal of Crohn'S & Colitis|December 26, 2014
High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacySteven A Hendler, Benjamin L Cohen, Jean-Frédéric Colombel, et al.
Evolutionary Human Sciences|October 15, 2025
Tracing contact and migration in pre-Bantu Southern Africa through lexical borrowingAnne-Maria Fehn, Bonny E Sands, Admire Phiri, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative ColitisBruce E Sands, Stefan Schreiber, Irina Blumenstein, et al.
Gastroenterology|February 5, 2008
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitisGilaad G Kaplan, Ellen P McCarthy, John Z Ayanian, et al.
Inflammatory Bowel Diseases|November 18, 2009
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's diseaseBruce E Sands, Eric W Jacobson, Thomas Sylwestrowicz, et al.
Pageof 52

Showing results (151-160 of 513) with videos related to

Sort By:
Pageof 52
Journal of Crohn'S & Colitis|May 28, 2013
Rates of pharmacologic venous thromboembolism prophylaxis in hospitalized patients with active ulcerative colitis: results from a tertiary care centerAndrew Tinsley, Steven Naymagon, Laura M Enomoto, et al.
The Journal of Biological Chemistry|April 21, 1995
Molecular cloning of the rat intestinal trefoil factor gene. Characterization of an intestinal goblet cell-associated promoterB E Sands, H Ogata, K Lynch-Devaney, et al.
Scandinavian Journal of Gastroenterology|June 26, 2020
Ileocolic anastomotic inflammation after resection for Crohn's disease indicates disease recurrence: a histopathologic studyRobert P Hirten, Simran Mashiana, Benjamin L Cohen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative ColitisParambir S Dulai, Brian G Feagan, Bruce E Sands, et al.
Clinical Pharmacology and Therapeutics|March 15, 2024
Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug-Drug InteractionsJie Shao, Marion Vetter, An Vermeulen, et al.
Journal of Crohn'S & Colitis|December 26, 2014
High-dose infliximab therapy in Crohn's disease: clinical experience, safety, and efficacySteven A Hendler, Benjamin L Cohen, Jean-Frédéric Colombel, et al.
Evolutionary Human Sciences|October 15, 2025
Tracing contact and migration in pre-Bantu Southern Africa through lexical borrowingAnne-Maria Fehn, Bonny E Sands, Admire Phiri, et al.
Journal of Crohn'S & Colitis|July 12, 2023
Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative ColitisBruce E Sands, Stefan Schreiber, Irina Blumenstein, et al.
Gastroenterology|February 5, 2008
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitisGilaad G Kaplan, Ellen P McCarthy, John Z Ayanian, et al.
Inflammatory Bowel Diseases|November 18, 2009
Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's diseaseBruce E Sands, Eric W Jacobson, Thomas Sylwestrowicz, et al.
Pageof 52